On June 16, Peijia Medical released the announcement of its audited results for the year ended December 31, 2023 (the “Reporting Period”). The results have been audited in accordance with International Standards on Auditing issued by the International Auditing and Assurance Standards Board. The Company’s auditor, PricewaterhouseCoopers, expressed an unqualified opinion in the independent auditor’s report.
The 2023 Annual Results remain the same as those disclosed on March 28, 2024, in the 2023 Unaudited Annual Results. The audited results of the Company for the Reporting Period are summarized below:
• The Group’s revenue increased by 75.9% yoy to RMB 440 million;
• The Group’s gross profit increased by 84.7% yoy to RMB 330 million, with the gross profit margin improving by 3.5 ppts to 73.8%;
• The Group’s expense ratios improved significantly: selling, administrative and R&D expense ratios decreased by 22.7, 17.1 and 82.2 ppts yoy, respectively;
•The segment loss of the TVT Business narrowed by 13.5% yoy, and the segment loss of NI Business was RMB 744,000. Trading in the shares of Peijia Medical (stock code: 09996.HK) resumed at 9:00 a.m. on June 17,2024.
